Trial · NCT02509507
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1: Monotherapy Group A | 23 | |
| Overall Study | STARTED | Part 1: Monotherapy Group B | 5 | |
| Overall Study | STARTED | Part 1: Combination Therapy Group A | 24 | |
| Overall Study | STARTED | Part 1: Combination Therapy Group B | 22 | |
| Overall Study | STARTED | Part 2: Hormone Receptor Positive Breast Cancer (HRBC) | 10 | |
| Overall Study | STARTED | Part 2: Triple Negative Breast Cancer (TNBC) | 18 | |
| Overall Study | STARTED | Part 2: Cutaneous Squamous Cell Carcinoma (CSCC) | 10 | |
| Overall Study | STARTED | Part 2: Basal Cell Carcinoma (BCC) | 5 | |
| Overall Study | STARTED | Part 2: Colorectal Adenocarcinoma (CRC) | 10 | |
| Overall Study | Received Talimogene Laherparepvec | Part 1: Monotherapy Group A | 23 | |
| Overall Study | Received Talimogene Laherparepvec | Part 1: Monotherapy Group B | 5 | |
| Overall Study | Received Talimogene Laherparepvec | Part 1: Combination Therapy Group A | 24 | |
| Overall Study | Received Talimogene Laherparepvec | Part 1: Combination Therapy Group B | 22 | |
| Overall Study | Received Talimogene Laherparepvec | Part 2: Hormone Receptor Positive Breast Cancer (HRBC) | 10 | |
| Overall Study | Received Talimogene Laherparepvec | Part 2: Triple Negative Breast Cancer (TNBC) | 18 | |
| Overall Study | Received Talimogene Laherparepvec | Part 2: Cutaneous Squamous Cell Carcinoma (CSCC) | 10 | |
| Overall Study | Received Talimogene Laherparepvec | Part 2: Basal Cell Carcinoma (BCC) | 5 | |
| Overall Study | Received Talimogene Laherparepvec | Part 2: Colorectal Adenocarcinoma (CRC) | 10 | |
| Overall Study | Received Pembrolizumab | Part 1: Monotherapy Group A | 0 | |
| Overall Study | Received Pembrolizumab | Part 1: Monotherapy Group B | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02509507/flow